Gene Regulatory Networks Analysis for Subtypes of Muscle-Invasive Bladder Cancer Based on Pathway

Recently, the Erdafitinib was approved by the U.S. Food and Drug Administration, which is the first targeted therapy drug for genetic alteration in metastatic urothelial carcinoma. Cancer genomics research is greatly encouraged. Currently, a great number of gene regulatory networks between different states have been constructed, which can reveal the difference of biological states. However, they have not yet been applied to the subtypes of bladder cancer. Furthermore, gene regulatory networks are not constructed on their pathway, which provide insights for multi-target gene therapy. In this paper, we proposed a new method that construct gene regulatory networks under different conditions. Specifically, gene regulatory networks under different molecular subtypes of bladder cancer based on pathway are constructed. Besides, the regulatory differences between molecular subtypes are analyzed. We find that many hub genes in differential networks are related to cancer or even bladder cancer and these genes are significant diversity in subtypes of bladder cancer. In addition, attention should be paid to the links between hub genes and others, especially when the hub genes are the (candidate) target of drugs.